ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- Efficacy assessment in phase I clinical trials: endpoints and challenges.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Review
- Nano-Based Drug Delivery Systems: Potential Developments in the Therapy of Metastatic Osteosarcoma-A Narrative Review.Pharmaceutics · 2023Review
- Association of survivin positive circulating tumor cell levels with immune escape and prognosis of osteosarcoma.Journal of cancer research and clinical oncology · 2023Article
- Long non-coding RNA and circular RNA and coding RNA profiling of plasma exosomes of osteosarcoma by RNA seq.Scientific data · 2023Article
- Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.Frontiers in oncology · 2023Review
- Article
- Activity of pazopanib inOncoscience · 2023Article
- Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response.Journal of hematology & oncology · 2022Article
- Ocular complications with the use of radium-223: a case series.Radiation oncology (London, England) · 2022Article
- Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.International journal of molecular sciences · 2022Review
- Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.Nanotheranostics · 2022Review
- Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.Frontiers in medicine · 2022Review
- Targeted alpha therapy with theFrontiers in medicine · 2022Article
- Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors.Cancer biotherapy & radiopharmaceuticals · 2021Article
- Review
- Dosimetric considerations ofPhysics in medicine and biology · 2020Article
- Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.Cancer biotherapy & radiopharmaceuticals · 2020Article
- Radiopharmaceutical therapy in cancer: clinical advances and challenges.Nature reviews. Drug discovery · 2020Review
- 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy.ESMO open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeThe prognosis of metastatic osteosarcoma continues to be poor. We hypothesized that alpha-emitting, bone-targeting radium 223 dichloride ( PATIENTS AND
methodsA 3+3 phase I, dose-escalation trial of
resultsAmong 18 patients enrolled (including 15 males) aged 15-71 years, tumor locations included spine (
conclusionsThe first evaluation of the safety and efficacy of an alpha particle in high-risk osteosarcoma shows that the recommended phase II dose for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.